Navigation Links
Thomson Reuters Publishes Pharma Matters White Paper, 'The Five Myths of Generic Competition'
Date:3/10/2009

Unique Survey Shows Much Room for Originator Pharmaceutical Companies to Improve Their Understanding of Generic Competition

PHILADELPHIA and LONDON, March 11 /PRNewswire/ -- The Healthcare and Science business of Thomson Reuters today released the white paper, "The Five Myths of Generic Competition," highlighting what originator pharmaceutical and biotech companies can do to improve their forecasting of the likely timing, source and intensity of competition from generic drugs.

The findings in this white paper are based on an independent survey of commercial professionals in pharmaceutical and biotech companies. The research was conducted by Thomson Reuters during May and June 2008.

The survey highlights a number of prevailing attitudes among commercial professionals, including:

  • Commercial professionals believe that little can be done to prevent sales erosion by generic drugs.
  • Commercial professionals feel that originator companies have little time or resources to devote to understanding generic competition.
  • Most executives surveyed assume that such research is already being conducted by someone else in their organization.

"The intelligence gathered and analyzed by our researchers tells us that these attitudes are based on some false assumptions," says Claude Basset, VP Specialty Markets, Thomson Reuters. "Understanding and forecasting generic competition remains undoubtedly a serious strategic challenge for anyone with a brand product on the market. It's clear, however, that there is more originators could do better - and earlier - to prepare for generic competition."

In analyzing the study findings, Thomson Reuters offers guidance on when and how best to improve competitive intelligence processes by focusing on more effective sources of long-range signals, and by providing brand teams with the resources and tools necessary to better understand generic competition.

To learn more about how companies can improve their understanding and forecasting of generic competition, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/generic_myths.pdf

"The Five Myths of Generic Competition" is part of Pharma Matters, a quarterly report series from Thomson Reuters that covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Newport Vision Premium(TM), Thomson Pharma(R), and the Thomson Messaging Mapping System(SM).

To sign up for the Thomson Reuters Pharma Matters series of publications visit:

http://scientific.thomsonreuters.com/info/matters/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thomson Reuters Study Tracks Impact of Recession on Hospitals
2. VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems
3. Molecular Oncology accepted into Thomson Reuters index
4. Thomson Reuters Releases 2009 Patent Focus Report
5. Kids and Their Families Are Hit Hardest During Flu Season, According to Thomson Reuters Study
6. Thomson Reuters Launches Liquent PublishPerfect(TM)
7. CMS Selects Thomson Reuters to Help Implement Medicare Medical Home Demonstration Project for Medicare Recipients
8. Thomson Reuters Installs Clinical Xpert at Catholic Healthcare West for HIS Downtime Solution
9. Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008
10. Tomball Regional Medical Center Selects Clinical Xpert(TM) from Thomson Reuters to Lead Quality Improvement Initiatives
11. Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... , ... Shark Finds and Kevin Harrington, along with the Product ... with Belly Bands. , Having a dog is great—except when it wets every couch, ... nothing works, get Belly Bands, the easiest way to stop dogs from wetting ...
(Date:2/5/2016)... ... February 05, 2016 , ... VeloReality ... lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability to an ... and manufacturing not only reduce the weight of the unit, they also enhance ...
(Date:2/5/2016)... ... 2016 , ... The Muscular Dystrophy Association and Sailormen Inc., ... 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise critical ... diseases that severely limit strength and mobility. , Now through March 20, ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an ... Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the ... successfully completed his first three-year term as chief and began a second three-year term ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends ... water may be safer than regular municipal or well water. The recent experience with ... Sharon Kleyne, could go a long way toward increasing public acceptance of recycled waste ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... Feb. 4, 2016 Frontier Pharma: Chronic ... First-in-Class Innovation Chronic Obstructive Pulmonary ... chronic inflammation of the airways and lungs. Persistent ... make the disease one of the leading causes ... in the world. COPD is linked to cumulative ...
Breaking Medicine Technology: